SuppreMol Raises ? 9.5 million in Extended Series D Financing Round
(Thomson Reuters ONE) -
SuppreMol GmbH /
SuppreMol Raises ? 9.5 million in Extended Series D Financing Round
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Munich, Germany, May 21(st), 2013: SuppreMol GmbH, a privately held
biopharmaceutical company developing novel therapies for the treatment of
autoimmune diseases, today announced the second closing of a series D financing
round receiving ? 9.5 million.
The second closing of this series D round was again led by MIG AG (Munich,
Germany) and Santo Holding GmbH (Holzkirchen, Germany) with BioMedPartners AG
(Basel, Switzerland) as co-lead investors; Max Planck Society and FCP Biotech
Holding GmbH invested also in this round. Together with the first closing from
September 2012 of ? 6.5 million, the total of this series D round is now ? 16
million.
SuppreMol will use the funds to further advance the Phase II studies of its lead
candidate SM101, a recombinant human soluble Fc-gamma receptor IIB (FcgRIIB) for
the treatment of Primary Immune Thrombocytopenia (ITP) and of Systemic Lupus
Erythematosus (SLE). ITP is a serious bleeding condition characterized by
deficient blood clotting due to auto-antibodies destroying the body's platelets.
SM101 has been granted orphan drug designation for the treatment of ITP in the
EU and US and started Phase IIa clinical studies late last year. SLE is a
chronic inflammatory autoimmune disease of unknown etiology affecting multiple
organs, which can lead to organ failure.
"I am impressed by the strong commitment of our investors", said Dr. Klaus
Schollmeier, who joined SuppreMol as CEO at the beginning of April 2013. "The
financing round will enable us to advance our lead product SM101 in Phase II
trials and further deepen our knowledge regarding the FcgRIIB-platform."
"This financing round signals strong confidence from our investors in SuppreMol
and its lead product SM101," said Dr. Thomas Hecht, Chairman of the Advisory
Board. "The additional funding will enable the company to push clinical trials
towards the next value enhancing milestones."
About SuppreMol
SuppreMol GmbH is a privately held biopharmaceutical company developing novel
therapeutics for the treatment of autoimmune and allergic diseases. The company
is pioneering the development of soluble Fc-gamma receptors (FcgRs), which are
recombinant autologous therapeutic proteins with a specific immunoregulatory
potential. The company's lead product SM101, a recombinant soluble FcgRIIB is in
Phase II clinical development for the treatment of Primary Immune
Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) and has potential
to treat Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol's
pipeline also includes two antibody development programs utilizing the
inhibitory effect of FcgRIIB suitable for alternative treatment strategies and
indications. SuppreMol was founded as a spin-off from the laboratory of Prof.
Dr. Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max Planck
Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has raised
about ? 51 million through private investors. Major shareholders in the company
include MIG Fonds, BioMedPartners AG, Santo Holding GmbH and FCP Biotech Holding
GmbH along with KfW Mittelstandsbank, Bayern Kapital GmbH, Max Planck Society,
and Z-Cube.
Contact
SuppreMol GmbH
Dr. Klaus Schollmeier
Chief Executive Officer
Tel: +49 89 30 90 50 680
E-mail: info(at)suppremol.com
www.suppremol.com
Press Release PDF:
http://hugin.info/155552/R/1703279/562979.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: SuppreMol GmbH via Thomson Reuters ONE
[HUG#1703279]
Unternehmensinformation / Kurzprofil:
Datum: 21.05.2013 - 10:35 Uhr
Sprache: Deutsch
News-ID 261802
Anzahl Zeichen: 4703
contact information:
Town:
Martinsried/Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SuppreMol Raises ? 9.5 million in Extended Series D Financing Round"
steht unter der journalistisch-redaktionellen Verantwortung von
SuppreMol GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
